Ludger News

March/April 2018



We hope you enjoy reading our newsletters! If you haven't already, please sign up to receive regular updates regarding technology. You can do this via our website, www.ludger.com

'IgE glycoforms' paper published in Journal of Allergy and Clinical Immunology



chnology & Bioenergy, a BBSRC NIBE

From our collaboration with Kings College London, as part of the 'GlycoShape: Defining and designing altered IgE glycoforms' project, we are pleased to announce the forthcoming publication of a paper in the Journal of Allergy and Clinical Immunology.

This paper describes the development of a tool to produce therapeutic IgE at high yields. Antitumour IgE activity has been demonstrated in a number of studies but it has been a challenge to produce high enough yields for preclinical and clinical studies. Once the high yield recombinant IgE was produced, analyses at Ludger were performed to assess the glycosylation profile, and these revealed the importance of Man5 glycans in antibody binding and functionality. This study, using IgE as an example, has demonstrated how novel antibody therapies can be developed with enhanced effector functions.

For more information and to view the full article, visit: www.ludger.com/news

Citation:

Crescioli S, Chiaruttini G, Mele S, Ilieva KM, Pellizzari G, Spencer DIR, Gardner RA, Lacy KE, Spicer JF, Tutt ANJ, Wagner GK, Karagiannis SN. Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology J Allergy Clin Immunol. 2018 Jan 19. pii: S0091-6749(18)30081-2. doi: 10.1016/j.jaci.2017.12.986. [Epub ahead of print]

ISO accreditation

We are pleased to report that Ludger has achieved accreditation to ISO9001:2015. This is the latest standard specifying requirements for a quality management system when an organization:

a) needs to demonstrate its ability to consistently provide products and services that meet customer requirements, and

b) aims to enhance customer satisfaction through the effective application of the system, including processes for improvement of the system and the assurance of conformity to customer requirements.



For more information, please visit our 'About Us' webpage

Analysis of intact released glycans

We have recently added a short slideshow on intact released glycan analysis to our website. This demonstrates our analytical approach, with example workflows and data for IgG and EPO.

Please take a look on our Glycan Analysis webpages



WCBP 2018, Washington D.C.

Claire Morgan and Rad Kozak presented two posters at this year's WCBP conference in Washington USA. The posters described the following:

a) analysis of sialylation in biopharmaceuticalsb) glycan characterisation of follicle stimulating hormone



They can be viewed by visiting our R&D for Biopharmaceuticals webpage

- in	FA202	0.2F	5.09%	
\$	A202	62	0.22%	
	FA2(8)G1	GIF	26.75	
	FA2(2)G1	510	1345	
	A-208223.1		0.14%	